AMR Centre teams up to tackle gonorrhoea
20 March 2020
The project is targeting multi-drug resistant gonorrhoea and will see AMRC undertake pre-clinical development to drive Microbiotix’s novel mechanism drug, a Trans T ribosome rescue inhibitor, through lead optimisation and into pre-clinical nomination.
The collaboration is currently receiving $2.86 million in grant funding and could receive an additional $16 million if certain development milestones are met. The funding is being offered by CARB-X, an organisation which helps accelerate global antibacterial projects.
Further reading: European Pharmaceutical Manufacturer
Author(s): European Pharmaceutical Manufacturer
Healthy Patients Smart Innovations
Ambassador Network
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!